Aristo Bio-Tech and Lifescience Limited (NSE:ARISTO)
India · Delayed Price · Currency is INR 94.05
-0.75 (-0.79%)
At close: Jun 15, 2026
NSE:ARISTO Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 3,637 | 3,181 | 2,451 | 2,179 | 1,658 |
Other Revenue | 0 | - | - | - | - |
| 3,637 | 3,181 | 2,451 | 2,179 | 1,658 | |
Revenue Growth (YoY) | 14.34% | 29.75% | 12.53% | 31.43% | -0.87% |
Cost of Revenue | 3,308 | 2,958 | 2,265 | 1,960 | 1,472 |
Gross Profit | 329.45 | 222.43 | 186.49 | 218.55 | 185.63 |
Selling, General & Admin | 49.7 | 41.4 | 37.28 | 58.42 | 53.94 |
Other Operating Expenses | 119.23 | 86.19 | 63.56 | 72.19 | 79.36 |
Operating Expenses | 198.18 | 153.62 | 116.55 | 145.97 | 144.29 |
Operating Income | 131.27 | 68.82 | 69.94 | 72.58 | 41.34 |
Interest Expense | -38.86 | -18.09 | -16.68 | -22.07 | -18.82 |
Interest & Investment Income | - | 0.57 | 0.46 | 0.56 | 0.24 |
Currency Exchange Gain (Loss) | - | 2.4 | 0.8 | -2.42 | -0.1 |
Other Non Operating Income (Expenses) | 4.56 | 0.29 | -0.45 | -1.26 | -2.42 |
EBT Excluding Unusual Items | 96.98 | 53.98 | 54.08 | 47.39 | 20.25 |
Gain (Loss) on Sale of Assets | - | 0.69 | -0 | - | 0.16 |
Asset Writedown | - | - | - | - | -0.6 |
Pretax Income | 96.98 | 54.67 | 54.08 | 47.39 | 19.8 |
Income Tax Expense | 25.15 | 14.04 | 15.12 | 11.77 | 5.47 |
Net Income | 71.83 | 40.63 | 38.96 | 35.62 | 14.34 |
Net Income to Common | 71.83 | 40.63 | 38.96 | 35.62 | 14.34 |
Net Income Growth | 76.78% | 4.30% | 9.36% | 148.44% | 33.29% |
Shares Outstanding (Basic) | 7 | 7 | 7 | 5 | 5 |
Shares Outstanding (Diluted) | 7 | 7 | 7 | 5 | 5 |
Shares Change (YoY) | 0.01% | - | 28.43% | 6.13% | - |
EPS (Basic) | 10.55 | 5.97 | 5.72 | 6.72 | 2.87 |
EPS (Diluted) | 10.55 | 5.97 | 5.72 | 6.72 | 2.87 |
EPS Growth | 76.77% | 4.34% | -14.88% | 134.14% | 33.27% |
Free Cash Flow | 54.83 | 49.1 | 10.45 | -68.44 | 35.29 |
Free Cash Flow Per Share | 8.05 | 7.21 | 1.54 | -12.91 | 7.07 |
Dividend Per Share | 0.600 | 0.500 | 0.400 | 0.250 | - |
Dividend Growth | 20.00% | 25.00% | 60.00% | - | - |
Gross Margin | 9.06% | 6.99% | 7.61% | 10.03% | 11.20% |
Operating Margin | 3.61% | 2.16% | 2.85% | 3.33% | 2.49% |
Profit Margin | 1.98% | 1.28% | 1.59% | 1.64% | 0.86% |
Free Cash Flow Margin | 1.51% | 1.54% | 0.43% | -3.14% | 2.13% |
EBITDA | 160.52 | 94.84 | 85.65 | 87.95 | 52.33 |
EBITDA Margin | 4.41% | 2.98% | 3.49% | 4.04% | 3.16% |
D&A For EBITDA | 29.25 | 26.02 | 15.71 | 15.36 | 10.99 |
EBIT | 131.27 | 68.82 | 69.94 | 72.58 | 41.34 |
EBIT Margin | 3.61% | 2.16% | 2.85% | 3.33% | 2.49% |
Effective Tax Rate | 25.93% | 25.68% | 27.96% | 24.83% | 27.60% |
Revenue as Reported | 3,642 | 3,185 | 2,453 | 2,182 | 1,660 |
Advertising Expenses | - | 0.14 | 0.3 | 0.25 | 0.04 |